{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:52:48Z","timestamp":1790005968902,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.metop.2024.100294","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T14:46:24Z","timestamp":1717598784000},"page":"100294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1250-7437","authenticated-orcid":false,"given":"Akira","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metop.2024.100294_bib1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(98)00090-7","article-title":"The UK prospective diabetes study","volume":"352","author":"Bailey","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.metop.2024.100294_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib6","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib7","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","article-title":"A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches","volume":"39","author":"Mima","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.metop.2024.100294_bib8","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41598-020-62579-7","article-title":"Linagliptin affects IRS1\/Akt signaling and prevents high glucose-induced apoptosis in podocytes","volume":"10","author":"Mima","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.metop.2024.100294_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115032","article-title":"Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: a narrative review","volume":"165","author":"Mima","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metop.2024.100294_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2023.100236","article-title":"Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: a systemic review and meta-analysis","volume":"17","author":"Mima","year":"2023","journal-title":"Metabol Open"},{"key":"10.1016\/j.metop.2024.100294_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","article-title":"Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease","volume":"32","author":"Mima","year":"2018","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.metop.2024.100294_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1574884713666181116100946","article-title":"The ascent of mineralocorticoid receptor antagonists in diabetic nephropathy","volume":"14","author":"Goenka","year":"2019","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.metop.2024.100294_bib13","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metop.2024.100294_bib14","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2023.100251","article-title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL\/min\/1.73 m(2)","volume":"19","author":"Mima","year":"2023","journal-title":"Metabol Open"},{"key":"10.1016\/j.metop.2024.100294_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190493","article-title":"Prognosis of chronic kidney disease with normal-range proteinuria: the CKD-ROUTE study","volume":"13","author":"Iimori","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.metop.2024.100294_bib18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.metop.2024.100294_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJM198312223092503","article-title":"Use of single voided urine samples to estimate quantitative proteinuria","volume":"309","author":"Ginsberg","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.21873\/invivo.13148","article-title":"Enarodustat treatment for renal anemia in patients with non-dialysis chronic kidney disease","volume":"37","author":"Mima","year":"2023","journal-title":"In Vivo"},{"key":"10.1016\/j.metop.2024.100294_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.ajkd.2007.09.004","article-title":"Modification of the modification of Diet in renal disease (MDRD) study equation for Japan","volume":"50","author":"Imai","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metop.2024.100294_bib22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metop.2024.100294_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22636-9","article-title":"Prediction of decreased estimated glomerular filtration rate using liver fibrosis markers: a renal biopsy-based study","volume":"12","author":"Mima","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.metop.2024.100294_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2023.100240","article-title":"Predictive significance of glomerular insulin receptor substrate-1 in patients with diabetic kidney disease","volume":"18","author":"Mima","year":"2023","journal-title":"Metabol Open"},{"key":"10.1016\/j.metop.2024.100294_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metop.2024.100294_bib26","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib28","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2024.100294_bib29","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s12325-021-01735-5","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease","volume":"38","author":"Mima","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.metop.2024.100294_bib30","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/db11-1824","article-title":"Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes","volume":"61","author":"Mima","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.metop.2024.100294_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metop.2024.100294_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.metop.2024.100294_bib33","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.metop.2024.100294_bib34","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2024.100294_bib35","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936824000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936824000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T21:47:01Z","timestamp":1718574421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936824000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":35,"alternative-id":["S2589936824000264"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2024.100294","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2024.100294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100294"}}